US guidelines advise every adult be screened once for hepatitis C, now that it is curable

US guidelines now recommend that every adult aged 18 to 79 be screened at least once for hepatitis C, a shift driven less by a change in the virus than by a change in what can be done about it [s1]. A short course of antiviral pills cures more than 95% of hepatitis C infections, which turned a hard-to-treat chronic infection into one worth finding in people who feel completely well [s1] [s2].

The answer, and why it changed

The US Preventive Services Task Force — an independent panel whose recommendations guide preventive care and insurance coverage — recommends screening for hepatitis C virus infection in all adults aged 18 to 79 years, a "B recommendation," meaning it concluded with moderate certainty that screening this group has a substantial net benefit [s1]. The recommendation applies to asymptomatic adults without known liver disease [s1]. It updated a narrower 2013 version, and the reason for widening it is the arithmetic of a curable disease: once treatment reliably works, the case for finding infections early — including in people who have no symptoms and no obvious risk factor — becomes far stronger [s1].

The virus is worth finding because it hides. Hepatitis C is the most common chronic blood-borne pathogen in the United States and a leading cause of complications from chronic liver disease, including cirrhosis and liver cancer [s1]. The task force notes it is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV [s1]. And the problem has been growing: acute hepatitis C cases rose roughly 3.8-fold over the decade preceding the recommendation, driven in part by increasing injection drug use and better surveillance [s1]. A silent infection that quietly scars the liver over years is exactly the kind of condition screening exists to catch.

What "curable" actually means here

The word "cure" is used precisely in hepatitis C, and it is unusual in chronic viral disease. The World Health Organization states that direct-acting antiviral medicines can cure more than 95% of people with hepatitis C infection [s2]. Treatment is short: the WHO describes a course usually lasting 12 to 24 weeks, and elsewhere notes these medicines can cure a severe, life-threatening chronic infection within 8 to 12 weeks of therapy in nearly all patients [s2]. WHO recommends direct-acting antivirals for adults, adolescents and children down to three years of age with chronic infection [s2].

That combination — a mostly symptomless infection, a simple blood test to find it, and an oral cure that works in the large majority — is why the screening recommendation reads the way it does. When a disease is both common and hard to treat, universal screening is a harder call, because finding cases does less good. When the treatment cures more than nine in ten, the calculus tips toward looking [s1] [s2].

The honest limits

Two caveats keep the picture accurate. First, a positive screening antibody test is a starting point, not a diagnosis of active infection: it indicates exposure, and a follow-up test for the virus itself is needed to confirm a current infection that warrants treatment. The screening recommendation is a recommendation to test, not a statement that a reactive result means active disease. Second, the barrier to eliminating hepatitis C is now access, not efficacy. The WHO notes that despite a cure existing, access to diagnosis and treatment remains low worldwide, and the great majority of infected people have never been diagnosed [s2]. A cure that people are never tested for, or cannot obtain, does not reach them — which is the entire logic of a screening recommendation aimed at people who feel fine.

What this leaves a reader with

The service-journalism answer is unusually clean for this beat: hepatitis C is common, usually silent, a leading driver of serious liver disease, and curable in more than 95% of cases with a short course of pills — and US guidance is that adults aged 18 to 79 be screened for it at least once [s1] [s2]. Whether and when to be tested, and how to interpret a result, is a short conversation to have with a clinician, and one the evidence makes a strong case for having.

This article is informational and is not medical advice.

Sources

• Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement — JAMA, 2020-03-02
• Hepatitis C (Fact Sheet) — World Health Organization